Journal
CHINESE JOURNAL OF CANCER
Volume 31, Issue 2, Pages 100-109Publisher
SUN YAT SEN UNIV MED SCI WHO
DOI: 10.5732/cjc.011.10326
Keywords
multidrug resistance; drug efflux transporter; cancer nanotechnology
Categories
Funding
- National Key Basic Research Program of China (973 projects) [2009CB930200]
- National Natural Science Foundation of China [30970784, 81171455]
- Chinese Academy of Sciences (CAS) Hundred Talents Program
- CAS Knowledge Innovation Program
Ask authors/readers for more resources
Multidrug resistance (MDR), which significantly decreases the efficacy of anticancer drugs and causes tumor recurrence, has been a major challenge in clinical cancer treatment with chemotherapeutic drugs for decades. Several mechanisms of overcoming drug resistance have been postulated. Well known P-glycoprotein (P-gp) and other drug efflux transporters are considered to be critical in pumping anticancer drugs out of cells and causing chemotherapy failure. Innovative theranostic (therapeutic and diagnostic) strategies with nanoparticles are rapidly evolving and are anticipated to offer opportunities to overcome these limits. In this review, we discuss the mechanisms of drug efflux-mediated resistance and the application of multiple nanoparticle-based platforms to overcome chemoresistance and improve therapeutic outcome.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available